{"date":"2025-10-24T00:00","headerImageUrl":"https://structuredproducts-ch-pub-uat.leonteq.com/product-news/product-homepage-banner/rfb_earnings_action_leonteq_structured_products_product+homepage+banner.jpg","subTitle":"Ahead of Q3 results: Novartis on track for further growth","windowTitle":"Earnings Action","category":"powerplay","title":"Earnings Action","body":"

Novartis is set to release its third-quarter results on October 28 before the market opens. The Switzerland-based global healthcare company is currently experiencing significant momentum. This positive development is driven by strong pipeline execution, new regulatory approvals, strategically valuable licensing agreements, and consistent capital returns to shareholders.<\/p>\n\n

Analysts surveyed by Refinitiv expect Novartis to report earnings per share (EPS) of USD 2.26 in its upcoming quarterly report \u2013 representing an increase of around 9.7% year over year. Revenue is projected to rise to USD 13.9 billion, marking an 8.4% increase compared to the same period last year.<\/p>\n\n

Depending on whether Novartis exceeds or misses expectations, stock price swings could be significant. For active investors, this presents interesting trading opportunities \u2013 especially with leveraged products.<\/div>\n

Leveraged Products on Novartis<\/h3>\n
\n \n \n \n <\/div>\n
<\/ltq-button><\/div>\n